Omar D. Lopez

ORCID: 0000-0003-2160-7488
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Computational Drug Discovery Methods
  • Cancer Genomics and Diagnostics
  • Hepatitis C virus research
  • Lung Cancer Treatments and Mutations
  • HIV/AIDS drug development and treatment
  • Molecular Biology Techniques and Applications
  • HER2/EGFR in Cancer Research
  • Asymmetric Synthesis and Catalysis
  • Cancer-related molecular mechanisms research
  • Carbohydrate Chemistry and Synthesis
  • Synthetic Organic Chemistry Methods
  • Oxidative Organic Chemistry Reactions
  • Click Chemistry and Applications
  • Biochemical and Molecular Research
  • Sarcoma Diagnosis and Treatment
  • Biosimilars and Bioanalytical Methods
  • Synthesis of Organic Compounds
  • RNA modifications and cancer
  • Hepatitis B Virus Studies
  • Synthesis of β-Lactam Compounds
  • Crystallization and Solubility Studies
  • Cancer therapeutics and mechanisms
  • Monoclonal and Polyclonal Antibodies Research
  • Chemical Synthesis and Analysis
  • X-ray Diffraction in Crystallography

National Cancer Institute
2020-2023

Center for Cancer Research
2023

Secretaría Nacional de Ciencia, Tecnología e Innovación
2022

Frederick National Laboratory for Cancer Research
2020

Bristol-Myers Squibb (United States)
2007-2017

Instituto de Investigación Biomédica de Málaga
2017

Texas Christian University
2014

Mexican Social Security Institute
2003

Hospital General De Zona
2003

The University of Texas at Austin
1999-2003

The biphenyl derivatives 2 and 3 are prototypes of a novel class NS5A replication complex inhibitors that demonstrate high inhibitory potency toward panel clinically relevant HCV strains encompassing genotypes 1–6. However, these compounds exhibit poor systemic exposure in rat pharmacokinetic studies after oral dosing. structure–activity relationship investigations improved the properties parent bis-phenylimidazole chemotype, culminating identification highly potent inhibitor daclatasvir...

10.1021/jm401836p article EN Journal of Medicinal Chemistry 2014-02-12

Lead inhibitors that target the function of hepatitis C virus (HCV) nonstructural 5A (NS5A) protein have been identified by phenotypic screening campaigns using HCV subgenomic replicons. The demonstration antiviral activity in HCV-infected subjects NS5A replication complex inhibitor (RCI) daclatasvir (1) spawned considerable interest this mechanistic approach. In Perspective, we summarize medicinal chemistry studies led to discovery 1 and other chemotypes for which resistance maps provide...

10.1021/jm401793m article EN Journal of Medicinal Chemistry 2014-02-03

ADVERTISEMENT RETURN TO ISSUEPREVCommunicationNEXTGeneral Strategies for the Synthesis of Major Classes C-Aryl GlycosidesDavid E. Kaelin, Omar D. Lopez, and Stephen F. MartinView Author Information Department Chemistry Biochemistry The University Texas, Austin, Texas 78712 Cite this: J. Am. Chem. Soc. 2001, 123, 28, 6937–6938Publication Date (Web):June 22, 2001Publication History Received3 April 2001Published online22 June inissue 1 July...

10.1021/ja0108640 article EN Journal of the American Chemical Society 2001-06-22

Abstract The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in search novel chemotherapeutics. publicly available characterization and compound screening data from assay have significantly contributed understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated given chemotherapeutic agent against long served as fingerprint presentations that encompass target information...

10.1158/1535-7163.mct-23-0267 article EN cc-by-nc-nd Molecular Cancer Therapeutics 2023-08-07

A series of symmetrical E-stilbene prolinamides that originated from the library-synthesized lead 3 was studied with respect to HCV genotype 1a (G-1a) and 1b (G-1b) replicon inhibition selectivity against BVDV cytotoxicity. SAR emerging an examination prolinamide cap region revealed 11 be a selective NS5A inhibitor exhibiting submicromolar potency both G-1a G-1b replicons. Additional structural refinements resulted in identification 30 as potent, dual G-1a/1b inhibitor.

10.1021/jm301796k article EN Journal of Medicinal Chemistry 2013-04-10

A medicinal chemistry campaign that was conducted to address a potential genotoxic liability associated with an aniline-derived scaffold in series of HCV NS5A inhibitors dual GT-1a/-1b inhibitory activity is described. Anilides 3b and 3c were used as vehicles explore structural modifications retained antiviral potency while removing the for metabolism-based unmasking embedded aniline. This effort resulted discovery highly potent biarylimidazole chemotype established benchmark replicon...

10.1021/jm4016203 article EN Journal of Medicinal Chemistry 2014-01-17

Abstract Microsporidia comprises a diverse group of obligate, intracellular, and spore-forming parasites that infect wide range animals. Among them, Enterocytozoon bieneusi is the most frequently reported species in humans other mammals birds. Data on epidemiology E. wildlife are limited. Hence, was investigated eight wild ungulate present Spain (genera Ammotragus, Capra, Capreolus, Cervus, Dama, Ovis, Rupicapra, Sus) by molecular methods. Faecal samples were collected from free-ranging (n =...

10.1093/mmy/myac070 article EN Medical Mycology 2022-09-01

ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTEndo-Selective Reactions of .alpha.,.beta.-Unsaturated Hexacarbonyldiiron Bridging Acyl Complexes with NitronesScott R. Gilbertson, David P. Dawson, Omar D. Lopez, and Kenneth Lee MarshallCite this: J. Am. Chem. Soc. 1995, 117, 15, 4431–4432Publication Date (Print):April 1, 1995Publication History Published online1 May 2002Published inissue 1 April...

10.1021/ja00120a039 article EN Journal of the American Chemical Society 1995-04-01

Daclatasvir is a first-in-class, potent, and selective inhibitor of the hepatitis C virus nonstructural protein 5A replication complex. In support nonclinical studies during discovery exploratory development, liquid chromatography–tandem mass spectrometry nuclear magnetic resonance were used in connection with synthetic radiosynthetic approaches to investigate biotransformation daclatasvir vitro cynomolgus monkeys, dogs, mice, rats. The results these indicated that disposition was...

10.1124/dmd.115.068866 article EN Drug Metabolism and Disposition 2016-03-30

ADVERTISEMENT RETURN TO ISSUEPREVCommunicationNEXTSynthesis of and Asymmetric Cycloaddition with Chiral Diiron Acyl ComplexesScott R. Gilbertson Omar D. LopezView Author Information Department Chemistry Washington University St. Louis, Missouri 63130 Cite this: J. Am. Chem. Soc. 1997, 119, 14, 3399–3400Publication Date (Web):April 9, 1997Publication History Received5 December 1996Published online9 April 1997Published inissue 1...

10.1021/ja964195f article EN Journal of the American Chemical Society 1997-04-01

Kinetic resolution is achieved in the reaction of racemic diiron complexes like 1 with chiral nitrone (−)-2. Oxidative removal metal and reductive cleavage N−O bond provides β-amino acids. This sequence was used synthesis acids as well corresponding β-lactams 4 (via 3).

10.1002/(sici)1521-3773(19990419)38:8<1116::aid-anie1116>3.0.co;2-m article EN Angewandte Chemie International Edition 1999-04-19

Abstract In this article, 5-aza-4′-thio-2′-β-fluoro-2′-deoxycytidine (F-aza-T-dCyd, NSC801845), a novel cytidine analog, is first disclosed and compared with T-dCyd, F-T-dCyd, aza-T-dCyd in cell culture mouse xenograft studies HCT-116 human colon carcinoma, OVCAR3 ovarian NCI-H23 NSCLC HL-60 leukemia, the PDX BL0382 bladder carcinoma. three of five lines (HCT-116, HL-60, BL-0382), F-aza-T-dCyd was more efficacious than aza-T-dCyd. Comparable activity observed for these two agents against...

10.1158/1535-7163.mct-20-0738 article EN Molecular Cancer Therapeutics 2021-04-01

ABSTRACT Daclatasvir (DCV) is a first-in-class hepatitis C virus (HCV) nonstructural 5A replication complex inhibitor (NS5A RCI) that clinically effective in interferon-free combinations with direct-acting antivirals (DAAs) targeting alternate HCV proteins. Recently, we reported NS5A RCI enhance inhibitory potential vitro , defining new class of inhibitors termed synergists (J. Sun, D. R. O’Boyle II, A. Fridell, Langley, C. Wang, S. Roberts, P. Nower, B. M. Johnson F. Moulin, J. Nophsker, Y....

10.1128/aac.02639-15 article EN Antimicrobial Agents and Chemotherapy 2015-12-29

An efficient large-scale synthesis of acid 1, a penultimate precursor to the HCV NS5A inhibitor BMS-986097, along with final API step are described. Three routes were devised for 1 at various stages program. The third generation route, one that proved scalable and is main subject this paper, features one-step Michael addition t-butyl 2-((diphenylmethylene)amino)acetate (24) (E)-benzyl 4-(1-hydroxycyclopropyl)but-2-enoate (28) followed by cyclization chiral separation form 27c, core skeleton...

10.1021/acs.joc.7b01852 article EN The Journal of Organic Chemistry 2017-09-07

The lack of effective methods to perform direct β-selective glycosylation reactions with 2-deoxy-1,4-dithio-D-erythro-pentofuranosides has long been a significant stumbling block for the multi-gram synthesis 4'-thio-2'-deoxy nucleosides. In addition, previously reported preparation appropriately substituted have proven problematic large scale synthesis. To address these issues, herein we describe modification and optimization allow convenient benzyl...

10.1080/15257770.2020.1832694 article EN public-domain Nucleosides Nucleotides & Nucleic Acids 2020-10-16
Coming Soon ...